These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 6489325)

  • 1. Antibacterial activity of ciprofloxacin in conventional tests and in a model of bacterial cystitis.
    Greenwood D; Baxter S; Cowlishaw A; Eley A; Slater GJ
    Eur J Clin Microbiol; 1984 Aug; 3(4):351-4. PubMed ID: 6489325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of E-3846, a new fluoroquinolone, in vitro and in experimental cystitis and pyelonephritis in rats.
    Gargallo D; Moros M; Coll R; Esteve M; Parés J; Xicota MA; Guinea J
    Antimicrob Agents Chemother; 1988 May; 32(5):636-41. PubMed ID: 3134844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population analysis of susceptibility to ciprofloxacin and nalidixic acid in Staphylococcus, Pseudomonas aeruginosa, and Enterobacteriaceae.
    Søgaard P; Gahrn-Hansen B
    Acta Pathol Microbiol Immunol Scand B; 1986 Oct; 94(5):351-6. PubMed ID: 3098043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid.
    Bauernfeind A; Petermüller C
    Eur J Clin Microbiol; 1983 Apr; 2(2):111-5. PubMed ID: 6222896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Laboratory evaluation of enoxacin: comparison with norfloxacin and nalidixic acid.
    Teoh-Chan CH; Cowlishaw A; Eley A; Slater G; Greenwood D
    J Antimicrob Chemother; 1985 Jan; 15(1):45-52. PubMed ID: 3156113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [In vitro antibacterial activity of ciprofloxacin against uropathogenic organisms].
    Allocati N; Catamo G; Cellini L
    Boll Soc Ital Biol Sper; 1984 Oct; 60(10):1927-33. PubMed ID: 6440583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ciprofloxacin in the treatment of urinary tract infection due to enterobacteria.
    Guibert J; Destrée D; Konopka C; Acar J
    Eur J Clin Microbiol; 1986 Apr; 5(2):247-8. PubMed ID: 2941292
    [No Abstract]   [Full Text] [Related]  

  • 8. The assessment of antimicrobial activity in an in-vitro model of the treatment of bacterial cystitis.
    Greenwood D
    J Antimicrob Chemother; 1984 May; 13 Suppl B():43-8. PubMed ID: 6234274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative in vitro activity of five quinoline derivatives and five other antimicrobial agents used in oral therapy.
    Hoogkamp-Korstanje JA
    Eur J Clin Microbiol; 1984 Aug; 3(4):333-8. PubMed ID: 6237901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The comparative in-vitro activity of norfloxacin, ciprofloxacin, enoxacin and nalidixic acid against 423 strains of gram-negative rods and staphylococci isolated from infected hospitalised patients.
    Guimaraes MA; Noone P
    J Antimicrob Chemother; 1986 Jan; 17(1):63-7. PubMed ID: 2936708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The comparative in-vitro activity of eight newer quinolones and nalidixic acid.
    King A; Phillips I
    J Antimicrob Chemother; 1986 Nov; 18 Suppl D():1-20. PubMed ID: 3468100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of ciprofloxacin (BAYo 9867) against Pseudomonas aeruginosa and ampicillin-resistant Enterobacteriaceae.
    Roy C; Foz A; Segura C; Tirado M; Teixell M; Teruel D
    Infection; 1983; 11(6):326-8. PubMed ID: 6421743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experience with ciprofloxacin in vitro and in vivo.
    Giamarellou H; Efstratiou A; Tsagarakis J; Petrikkos G; Daikos GK
    Arzneimittelforschung; 1984; 34(12):1775-8. PubMed ID: 6442151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In-vitro studies with ciprofloxacin, a new 4-quinolone compound.
    Reeves DS; Bywater MJ; Holt HA; White LO
    J Antimicrob Chemother; 1984 Apr; 13(4):333-46. PubMed ID: 6233250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The in vitro and in vivo activity of ciprofloxacin.
    Zeiler HJ; Grohe K
    Eur J Clin Microbiol; 1984 Aug; 3(4):339-43. PubMed ID: 6237902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trends in quinolone susceptibility of Enterobacteriaceae among inpatients of a large university hospital: 1992-98.
    Robert J; Cambau E; Grenet K; Trystram D; Péan Y; Fiévet MH; Jarlier V
    Clin Microbiol Infect; 2001 Oct; 7(10):553-61. PubMed ID: 11683796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The in-vitro activity of ciprofloxacin compared with that of norfloxacin and nalidixic acid.
    King A; Shannon K; Phillips I
    J Antimicrob Chemother; 1984 Apr; 13(4):325-31. PubMed ID: 6233249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative "in vitro" activity of ciprofloxacin (Bay o9867) and other antimicrobial agents against urinary bacterial isolates.
    Piccolomini R; Ravagnan G
    Chemioterapia; 1986 Aug; 5(4):249-56. PubMed ID: 3769047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ciprofloxacin in the treatment of urinary tract infection in patients with multiple sclerosis.
    Van Poppel H; Wegge M; Dammekens H; Chysky V
    Eur J Clin Microbiol; 1986 Apr; 5(2):251-3. PubMed ID: 2941294
    [No Abstract]   [Full Text] [Related]  

  • 20. A laboratory assessment of ciprofloxacin and comparable antimicrobial agents.
    Shrire L; Saunders J; Traynor R; Koornhof HJ
    Eur J Clin Microbiol; 1984 Aug; 3(4):328-32. PubMed ID: 6237900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.